CollabRx Announces Adrienne Craig-Kennard as Vice President of Global Business Development and Strategic Alliances
January 19 2016 - 7:00AM
CollabRx, Inc., a leading clinical decision support company and
wholly owned subsidiary of Rennova Health, Inc. (NASDAQ:RNVA) today
announced Adrienne Craig-Kennard will serve as Vice President of
Global Business Development and Strategic Alliances.
Craig-Kennard, an expert in international business development
with more than 15 years experience in the pharmaceutical,
biotechnology, and bioinformatics industries, will lead development
and strategy for CollabRx. She has acted in research and product
development roles in addition to business development and COO
positions in her previous work.
“Adrienne has a brilliant track record as an executive in our
industry,” said Thomas Mika, CEO of CollabRx. “Her ability to work
and think as a scientist as well as a businesswoman has led to
global success and we could not be more thrilled to have her join
our team.”
“CollabRx’s ability to deliver expert solutions in precision
oncology is paramount in today’s market where physicians,
laboratories, payers and providers strive to achieve standardized,
evidence-based care and superior clinical outcomes,” said Adrienne
Craig-Kennard. ‘My background, coupled with the opportunity to
become an integral part in the advancement of oncology care are an
ideal fit.”
Most recently Craig Kennard was Vice President of Global
Clinical Informatics Sales for Strand Life Sciences where she led
global sales of software as well as services for translational
research and next generation sequencing-based clinical
diagnostics.
Craig-Kennard received her Bachelor of Science in Chemistry from
the University of California, Berkeley and an M.B.A. from the
Grenoble Graduate School of Business in France.
About CollabRx, Inc.
CollabRx is a clinical decision-support company delivering
expert solutions in precision oncology that enable physicians,
laboratories, payers, and providers to achieve standardized,
evidence-based care and superior clinical outcomes. CollabRx uses
information technology to aggregate and contextualize the world’s
knowledge on genomics-based medicine with specific insights from
the nation’s top cancer experts, starting with the area of greatest
need: advanced cancers in patients who have effectively exhausted
the standard of care. More information may be obtained at
http://www.collabrx.com.
About Rennova Health, Inc.
Rennova Health (Nasdaq:RNVA) owns and operates five diagnostics
laboratories across the United States that provide clinical testing
services specializing in toxicology testing for pain management
clinics, drug and alcohol rehabilitation facilities and
neurotransmitter testing. It offers its customers a complete,
turnkey software product including: a proprietary laboratory
ordering and reporting application, an advanced laboratory
information management system, electronic health records, and an
industry-leading platform for interpreting and reporting complex
test results to physicians. Rennova's software is differentiated
from that of its competitors by the breadth of its services, each
of which is branded separately and is made available to physician
groups in whole or in part. The software permits efficient and easy
ordering and reporting, electronic health records integration,
medical billing services and compliance, and diagnostic
interpretation. For more information
see www.rennovahealth.com.
Media Contact:
Marla Kertzman for CollabRx
408 482 3546
marla@thoroughbred-communications.com
Rennova Health Company Contact:
Tiffany VanDeMark
Director of Marketing
561 666 9821
tvandemark@rennovahealthms.com
(MM) (NASDAQ:CLRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
(MM) (NASDAQ:CLRX)
Historical Stock Chart
From Sep 2023 to Sep 2024